Key facts
- This page summarizes Arturo Molina MD's Form 4 filing for SUTRO BIOPHARMA, INC. (STRO).
- 5 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 07 Mar 2022, 18:20.
Arturo Molina MD - 04 Mar 2022 Form 4 Insider Report for SUTRO BIOPHARMA, INC. (STRO)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- STRO
- Reported as of
- 04 Mar 2022
- Net transaction value
- -$35,580
- SEC form
- 4
- Accepted by SEC
- 07 Mar 2022, 18:20:36 UTC
- Prior SEC filing
- 01 Feb 2022
- Next SEC filing
- 09 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Edward C. Albini as attorney-in-fact for Arturo Molina, M.D.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Arturo Molina MD filed Form 4 for SUTRO BIOPHARMA, INC. (STRO) on 07 Mar 2022.
Change
- Previous filing in this sequence was filed on 01 Feb 2022.
- Current net transaction value: -$35,580.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
STRO
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +12,500
- Change %
- +42%
- Price
- Shares after
- 42,091
- Date
- 05 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
STRO
transaction
Common Stock
Tax liability
- Transaction value
- $35,580
- Shares
- -4,355
- Change %
- -10%
- Price
- $8.17
- Shares after
- 37,736
- Date
- 05 Mar 2022
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
STRO
transaction
Derivative
Stock Option (right to buy Common Stock)
Award
- Transaction value
- $0
- Shares
- +52,000
- Change %
- Price
- $0.000000
- Shares after
- 52,000
- Date
- 04 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 52,000
- Exercise price
- $8.17
- Footnotes
- F3
STRO
transaction
Derivative
Restricted Stock Unit (RSU)
Award
- Transaction value
- $0
- Shares
- +39,000
- Change %
- Price
- $0.000000
- Shares after
- 39,000
- Date
- 04 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 39,000
- Exercise price
- Footnotes
- F1, F4
STRO
transaction
Derivative
Restricted Stock Unit (RSU)
Options Exercise
- Transaction value
- $0
- Shares
- -12,500
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 37,500
- Date
- 05 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,500
- Exercise price
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
Footnote F2
Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.
Footnote F3
The option vests as to 2.0833% of the total shares monthly, beginning on April 4, 2022, with 100% of the total shares vested and exercisable on March 4, 2026, subject to the reporting person's provision of service to the issuer on each vesting date.
Footnote F4
The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date.
Footnote F5
The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date.